Case Reports in Rheumatology

Case Report

Hepatitis E during Tocilizumab Therapy in a Patient with Rheumatoid Arthritis: Case Report and Literature Review

Table 2

Summary of cases of hepatitis E during treatment of rheumatoid arthritis.
NumberFirst authorYearReferenceSexAgebDMARDs/tsDMARDsStopping bDMARDs/tsDMARDscsDMARDsStopping csDMARDsPSL (mg/day)HEV genotypeRibavirinPeriods for disappearance of HEV RNAPrognosis
1Sugawara2009[12]M60IFXNAMTX, BUC (+)4(−)NADied due to fulminant hepatitis
2Bauer2013[13]F68ABAYesLEFYes53(−)NAImproved
3Roux2013[14]M55RTXYesMTXYes(+)3(+)3 monthsImproved
4Bauer2015[15]F62IFXYesMTXYes(−)NA(−)4 weeksImproved
5Bauer2015[15]M72RTXNoMTX, LEFYes(−)NA(−)NAImproved
6Bauer2015[15]F49TCZYes(−)Yes33f(−)6 weeksImproved
7Bauer2015[15]F69ABAYesLEFYes53f(−)6 weeksImproved
8Bauer2015[15]M69RTXNoMTXNo(−)NA(+)10.5 weeksImproved
9Bauer2015[15]M61RTXNoLEFYes3NA(−)8 weeksImproved
10Bauer2015[15]F53ABAYesMTXYes(−)NA(−)9 weeksImproved
11Bauer2015[15]F44RTXYesMTXYes(−)3c(−)9.5 weeksImproved
12Bauer2015[15]F55ETNYesMTXYes(−)NA(−)4 weeksImproved
13Bauer2015[15]F60ADAYesMTXYes43f(−)8 weeksImproved
14Bauer2015[15]M59TCZYesMTXYes7NA(−)4 weeksImproved
15Schultze2015[16]F68(−) MTXYes5 NA(−)40 daysImproved
16Leloy2015[17]F33TCZYes(−) (−)NA(−)NAImproved
17Kanda2015[18]F64(−) MTX, BUCNA(−)3(−)NAImproved
18Kanda2015[18]F74TOFYes(−) (+)3(−)NAImproved
19Kanda2015[18]F52(−) MTXNA(−)3(−)NAImproved
20Verhoeven2016[19]F51RTXYes(−) (−)NA(+)2 monthsImproved
21Kobayashi2017[20]F58(−) BUC, MIZ, ACTNo5NA(−)NAImproved
22Kobayashi2017[20]M61ETNYesMTXYes3NA(−)NAImproved
23Kobayashi2017[20]M67(−) MTX, TACYes5NA(−)NAImproved
24Kobayashi2017[20]F52(−) MTX, MIZ, TACYes4NA(−)NAImproved
25van Bijnen2017[21]M63ADAYesMTXYes33(+)42 days after ribavirinChronic infection˗improved
26Our case  F63TCZYes(−) 33e(−)6 weeksImproved
DMARDs, disease-modifying antirheumatic drugs; bDMARDs, biologic DMARDs; csDMARDs, conventional synthetic DMARDs; PSL, prednisolone/prednisone; HEV, hepatitis E virus; IFX, infliximab; RTX, rituximab; TCZ, tocilizumab; ABA, abatacept; ETN, etanercept; TOF, tofacitinib; MTX, methotrexate; BUC, bucillamine; LEF, leflunomide; MIZ, mizoribine; ACT, actarit; TAC, tacrolimus; NA, not available. Dose is not available; weekly dosage.